We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $152.67, marking a +1.4% move from the previous day. Meanwhile, the Dow experienced a drop of 0.36%, and the technology-dominated Nasdaq saw an increase of 0.45%.
The HIV and hepatitis C drugmaker's stock has climbed by 2.6% in the past month, exceeding the Medical sector's loss of 3.65% and the S&P 500's gain of 1.27%.
Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 12.96% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $7.79 billion, indicating a 0.3% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.48 per share and a revenue of $30.74 billion, representing changes of -105.89% and +4.4%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.9% higher. Gilead Sciences is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 165, placing it within the bottom 33% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $152.67, marking a +1.4% move from the previous day. Meanwhile, the Dow experienced a drop of 0.36%, and the technology-dominated Nasdaq saw an increase of 0.45%.
The HIV and hepatitis C drugmaker's stock has climbed by 2.6% in the past month, exceeding the Medical sector's loss of 3.65% and the S&P 500's gain of 1.27%.
Market participants will be closely following the financial results of Gilead Sciences in its upcoming release. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 12.96% decrease from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $7.79 billion, indicating a 0.3% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.48 per share and a revenue of $30.74 billion, representing changes of -105.89% and +4.4%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 3.9% higher. Gilead Sciences is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 165, placing it within the bottom 33% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.